As­traZeneca shells out $775M to set­tle Ul­tomiris patent suit with Roche

A month af­ter re­ports first emerged that Roche and As­traZeneca have set­tled a years­long patent bat­tle over Ul­tomiris, we now know how much As­traZeneca paid to free it­self of the le­gal en­tan­gle­ments: $775 mil­lion.

Roche sub­sidiary Chugai first sued Alex­ion in 2018, be­fore Ul­tomiris was ap­proved and when it was still known as ravulizum­ab, al­leg­ing that Alex­ion used a Chugai tech­nol­o­gy in cre­at­ing the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER